Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All paxlovid studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchPaxlovidPaxlovid (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   All Outcomes    Recent:   

Effectiveness of Paxlovid in the treatment of the SARS-CoV-2 Omicron variant infection in children with hematologic malignancies: a retrospective cohort study

Deng et al., Translational Cancer Research, doi:10.21037/tcr-24-70
Aug 2024  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Time to viral- -17% Improvement Relative Risk Rebound -105% Paxlovid for COVID-19  Deng et al.  EARLY TREATMENT Is early treatment with paxlovid beneficial for COVID-19? Retrospective 42 patients in China (December 2022 - March 2023) No significant difference in viral clearance c19early.org Deng et al., Translational Cancer Rese.., Aug 2024 Favorspaxlovid Favorscontrol 0 0.5 1 1.5 2+
Retrospective 42 children with hematologic malignancies (HMs) and SARS-CoV-2 omicron infection showing no significant difference in clinical outcomes or viral clearance with paxlovid after propensity score matching.
Confounding by contraindication. Hoertel et al. find that over 50% of patients that died had a contraindication for the use of Paxlovid1. Retrospective studies that do not exclude contraindicated patients may significantly overestimate efficacy.
Black box warning. The FDA notes that "severe, life-threatening, and/or fatal adverse reactions due to drug interactions have been reported in patients treated with paxlovid"2.
Kamo et al. show significantly increased risk of acute kidney injury. Resistant variants are likely4,5.
time to viral-, 16.7% higher, relative time 1.17, p = 0.71, treatment 9, control 9, propensity score matching.
rebound, 105.0% higher, OR 2.05, p = 0.57, treatment 21, control 21, adjusted per study, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Deng et al., 31 Aug 2024, retrospective, China, peer-reviewed, 7 authors, study period 1 December, 2022 - 1 March, 2023. Contact: caoqing@scmc.com.cn.
This PaperPaxlovidAll
Effectiveness of Paxlovid in the treatment of the SARS-CoV-2 Omicron variant infection in children with hematologic malignancies: a retrospective cohort study
Xiaoxia Deng, Yuelian Jiang, Wenjuan Chen, Xia Qin, Jing Chen, Hao Li, MD Qing Cao
Translational Cancer Research, doi:10.21037/tcr-24-70
Background: Patients with hematologic malignancies (HMs) may be immunocompromised after receiving anti-tumor therapy. Those who also have the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus infection face many challenges, including a lack of effective antiviral drugs. This study aimed to investigate the clinical features of the SARS-CoV-2 Omicron variant infection in children with HMs, and the effectiveness of Paxlovid. Methods: A retrospective, non-randomized study was conducted on pediatric patients with HMs infected with the SARS-CoV-2 Omicron variant who had been admitted to the Shanghai Children's Medical Center, Shanghai, China from December 1, 2022 to March 1, 2023. The Paxlovid-treated group (Group P) comprised 21 patients, and the non-Paxlovid-treated group (Group N) comprised 21 patients. The patients' demographic data, clinical features, and therapeutic outcomes were collected. Statistical tests were used to evaluate the effectiveness of the treatment and related factors. Results: The clinical course of the SARS-CoV-2 Omicron variant infection for most of the children with HMs was non-severe (97.6%), and only one child progressed to severe disease (2.4%). The most common symptoms were fever (66.7%) and cough (52.4%). Compared with the children in Group N, those in Group P had worse clinical characteristics, including those who previously underwent hematopoietic stem cell transplantation (HSCT) or chimeric antigen receptor T (CAR-T) cell treatment (71.4% vs. 28.6%, P=0.005), and those in the myelosuppressive phase (57.1% vs. 4.8%, P<0.001). Most of the children in Group P were treated with more than two types of antibiotics (76.2% vs. 42.9%, P=0.02). The patients treated with Paxlovid within 5 days of diagnosis had a median viral clearance time of 5 days [interquartile range (IQR), 4-8 days], which was significantly shorter than that of the patients who were not treated with Paxlovid (P=0.03). There were no significant differences in the clinical outcomes between the two groups after the propensity score matching (PSM) analyses. Eight patients (19%) had repeat-positive (re-positive) test results. No factor was found to be statistically significant in predicting re-positive test results based on the binary logistic regression analysis. Conclusions: Administering Paxlovid within 5 days of the diagnosis of the SARS-CoV-2 Omicron variant infection in children may effectively shorten the clearance time of the virus, but there is still the possibility the patients may have re-positive test results.
References
Cesaro, Mikulska, Hirsch, Update of recommendations for the management of COVID-19 in patients with haematological malignancies, haematopoietic cell transplantation and CAR T therapy, from the 2022 European Conference on Infections in Leukaemia (ECIL 9), Leukemia
Chien, Peterson, Young, Outcomes of breakthrough COVID-19 infections in patients with hematologic malignancies, Blood Adv
Haeusler, Ammann, Carlesse, SARS-CoV-2 in children with cancer or after haematopoietic stem cell transplant: An analysis of 131 patients, Eur J Cancer
Hall, Teh, COVID-19 Vaccination in Patients With Cancer and Patients Receiving HSCT or CAR-T Therapy: Immune Response, Real-World Effectiveness, and Implications for the Future, J Infect Dis
Hashmi, Bodea, Patni, COVID-19 in Pediatric Patients With Acute Lymphoblastic Leukemia or Lymphoma, JAMA Netw Open
Ichikawa, Tamura, Takahata, Prolonged shedding of viable SARS-CoV-2 in immunocompromised patients with haematological malignancies: A prospective study, Br J Haematol
Katsuya, Yoshida, Takashima, Immunogenicity after vaccination of COVID-19 vaccines in patients with cancer: a prospective, single center, observational study, Int J Clin Oncol
Najjar-Debbiny, Gronich, Weber, Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients, Clin Infect Dis
New, Cham, Smith, Effects of antineoplastic and immunomodulating agents on postvaccination SARS-CoV-2 breakthrough infections, antibody response, and serological cytokine profile, J Immunother Cancer
Saravolatz, Depcinski, Sharma, Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs, Clin Infect Dis
Wekking, Senevirathne, Pearce, The impact of COVID-19 on cancer patients, Cytokine Growth Factor Rev
{ 'indexed': {'date-parts': [[2024, 8, 30]], 'date-time': '2024-08-30T00:39:13Z', 'timestamp': 1724978353632}, 'reference-count': 0, 'publisher': 'AME Publishing Company', 'issue': '8', 'content-domain': {'domain': ['amegroups.com'], 'crossmark-restriction': False}, 'short-container-title': ['Transl Cancer Res'], 'published-print': {'date-parts': [[2024, 8]]}, 'DOI': '10.21037/tcr-24-70', 'type': 'journal-article', 'created': {'date-parts': [[2024, 8, 12]], 'date-time': '2024-08-12T07:11:30Z', 'timestamp': 1723446690000}, 'page': '4219-4230', 'update-policy': 'http://dx.doi.org/10.21037/ame_crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': [ 'Effectiveness of Paxlovid in the treatment of the SARS-CoV-2 Omicron variant infection in ' 'children with hematologic malignancies: a retrospective cohort study'], 'prefix': '10.21037', 'volume': '13', 'author': [ {'given': 'Xiaoxia', 'family': 'Deng', 'sequence': 'first', 'affiliation': []}, {'given': 'Yuelian', 'family': 'Jiang', 'sequence': 'additional', 'affiliation': []}, {'given': 'Wenjuan', 'family': 'Chen', 'sequence': 'additional', 'affiliation': []}, {'given': 'Xia', 'family': 'Qin', 'sequence': 'additional', 'affiliation': []}, {'given': 'Jing', 'family': 'Chen', 'sequence': 'additional', 'affiliation': []}, {'given': 'Hao', 'family': 'Li', 'sequence': 'additional', 'affiliation': []}, {'given': 'Qing', 'family': 'Cao', 'sequence': 'additional', 'affiliation': []}], 'member': '8611', 'published-online': {'date-parts': [[2024, 8]]}, 'container-title': ['Translational Cancer Research'], 'original-title': [], 'link': [ { 'URL': 'https://tcr.amegroups.com/article/download/88997/pdf', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2024, 8, 29]], 'date-time': '2024-08-29T07:54:35Z', 'timestamp': 1724918075000}, 'score': 1, 'resource': {'primary': {'URL': 'https://tcr.amegroups.com/article/view/88997/html'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2024, 8]]}, 'references-count': 0, 'journal-issue': { 'issue': '8', 'published-online': {'date-parts': [[2024, 8]]}, 'published-print': {'date-parts': [[2024, 8]]}}, 'URL': 'http://dx.doi.org/10.21037/tcr-24-70', 'relation': {}, 'ISSN': ['2218-676X', '2219-6803'], 'issn-type': [{'type': 'print', 'value': '2218-676X'}, {'type': 'electronic', 'value': '2219-6803'}], 'subject': [], 'published': {'date-parts': [[2024, 8]]}}
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit